Replacement Appendix 3X - Damian Clarke-Bruce
Released
Released
Announcement PDF
Appendix 3X
Initial Director’s Interest Notice
Appendix 3X
Rule 3.19A.1
Initial Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information and
documents given to ASX become ASX’s property and may be made public.
Introduced 30/9/2001.
Name of entity:
RACE ONCOLOGY LIMITED
ABN 61 149 318 749
We (the entity) give ASX the following information under listing rule 3.19A.1 and as
agent for the director for the purposes of section 205G of the Corporations Act.
Name of Director
Damian Clarke-Bruce
Date of appointment
1 February 2023
Part 1 - Director’s relevant interests in securities of which the director is the registered holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Number & class of securities
6,818 fully paid ordinary shares
+ See chapter 19 for defined terms.
11/3/2002
Appendix 3X Page 1
Appendix 3X
Initial Director’s Interest Notice
Part 2 – Director’s relevant interests in securities of which the director is not the registered
holder
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Name of holder & nature of interest
Number & class of Securities
Nil
Nil
Note: Provide details of the circumstances giving
rise to the relevant interest.
Part 3 – Director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
Executive Services Agreement
Nature of interest
Direct
Name of registered holder
(if issued securities)
N/A
No. and class of securities to which 755,671 options exercisable at $3.30 each and
interest relates
expiring 5 years from the date of issue (subject
to shareholder approval on 21 February 2023)
+ See chapter 19 for defined terms.
Appendix 3X Page 2
11/3/2002
Share your feedback
Discover